Osprey Medical (ASX: OSP) is pleased to announce that the Company is a winner of the prestigious Supplier Horizon Award from Premier Inc., one of the leading Group Purchasing Organizations (GPOs) in the US with over 4,100 member hospitals in its network. Osprey was one of nine suppliers this year to receive this prestigious award and was recognized for its support of Premier members through exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs.
Osprey Medical (ASX: OSP) today announced a strategic alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, Middle East, Africa, Central Asia and Turkey. Osprey’s DyeVert contrast minimization devices, complemented by GE Healthcare’s range of iodinated x-ray contrast media, offer healthcare professionals a technology platform to address the rising problem of Acute Kidney Injury (AKI) following interventional coronary angiograms in patients with Chronic Kidney Disease (CKD).
Osprey Medical (ASX: OSP) today announces its response to the US President signing an Executive Order aimed at transforming kidney care for more than 37 million Americans with some form of kidney disease. The initiative seeks to prevent kidney failure through better diagnosis, treatment and preventative care.
Osprey Medical (ASX: OSP) today announces that Dr Anand Prasad, M.D., Director of the Cardiac Catheterization Laboratory at University Health System and Associate Professor of Medicine at UT Health Science Centre at San Antonio, Texas presented the Acute Kidney Injury (AKI) Burden of Illness Study1 at the Premier Breakthroughs 2019 Conference and Exhibition in Nashville, Tennessee on behalf of the study investigators.
As part of Premier’s Technology Breakthroughs Program, Osprey Medical, Inc. has been awarded a group purchasing agreement giving Premier’s ~4,000 U.S. hospitals access to purchase the DyeVert Plus Contrast Reduction System. Osprey Medical’s DyeVert Plus System is the only technology cleared by the U. S. Food & Drug Administration for contrast reduction and real-time monitoring of dye dose delivered to patients during a coronary or peripheral angiogram. Use of the DyeVert Plus System has resulted in a mean 40% contrast media (dye) volume reduction, which has been shown to be statistically significant and clinically meaningful.
Osprey Medical (ASX:OSP) is pleased to announce a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys™ campaign. The campaign aims to increase awareness of strategies to help address acute kidney injury (AKI) following normal heart imaging procedures (angiograms) in patients with chronic kidney disease (CKD). As part of the campaign, Osprey Medical and GE Healthcare will sponsor a number of educational programs and seminars for healthcare professionals on how to address the risk of AKI.
San Antonio’s University Hospital is one of the first hospitals to use a device called DyeVert Plus. Bluetooth technology embedded in the syringe uses wireless transmission to track exactly how much dye is used for each image. Tests of the new device show it can reduce the amount of dye used in heart procedures on kidney patients by as much as 40 percent.
Osprey Medical today announced that it has received US FDA 510(k) clearance for its advanced DyeVert™ PLUS Contrast Reduction System. This new platform augments Osprey’s current technology with the capability to actively manage dye administration during coronary interventions.
DyeVert PLUS received European CE Mark in 4Q 2016. The company further validated its dye savings capabilities through initial market testing with multiple physicians in Germany and Italy, which showed a 44% contrast reduction. The product received strong positive feedback on the utility of real-time contrast monitoring and ease-of-use.
Osprey Medical is pleased to announce the expansion of its portfolio with introduction of the DyeVert™ PLUS Contrast Modulation/Monitoring System. This new platform integrates the current DyeVert technology with substantial patient management and monitoring capabilities. The system has received European CE Mark and FDA clearance is pending. The Company anticipates US availability Q1 2017.
Highlighted at the Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, held October 29 – November 2 in Washington DC, the DyeVert PLUS received publicity via both podium presence and considerable booth exposure. As one of the world’s largest gatherings of heart specialists, TCT hosts over 6,000 medical professionals in the fields of interventional cardiology and vascular medicine.
Osprey Medical is pleased to announce the Company’s scheduled presentations for the upcoming Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, which is being held October 29 to November 2 in Washington, DC.
The TC is a leading international cardiovascular conference and one of the world’s largest gathering of heart specialists. The meeting hosts around 11,000 attendees with over 6,000 international medical professionals in the fields of interventional cardiology and vascular medicine.